- Home
- PMVP vs PYXS Comparison
PMVP vs PYXS Comparison
Compare PMVP & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- PYXS
- Stock Information
- Founded
- PMVP 2013
- PYXS 2018
- Country
- PMVP United States
- PYXS United States
- Employees
- PMVP N/A
- PYXS 44
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- PYXS Health Care
- Exchange
- PMVP Nasdaq
- PYXS Nasdaq
- Market Cap
- PMVP 74.7M
- PYXS 243.5M
- IPO Year
- PMVP 2020
- PYXS 2021
- Fundamental
- Price
- PMVP $1.29
- PYXS $4.07
- Analyst Decision
- PMVP Strong Buy
- PYXS Strong Buy
- Analyst Count
- PMVP 1
- PYXS 5
- Target Price
- PMVP $5.00
- PYXS $8.25
- AVG Volume (30 Days)
- PMVP 731.5K
- PYXS 787.5K
- Earning Date
- PMVP 11-07-2025
- PYXS 11-03-2025
- Dividend Yield
- PMVP N/A
- PYXS N/A
- EPS Growth
- PMVP N/A
- PYXS N/A
- EPS
- PMVP N/A
- PYXS N/A
- Revenue
- PMVP N/A
- PYXS $2,820,000.00
- Revenue This Year
- PMVP N/A
- PYXS N/A
- Revenue Next Year
- PMVP N/A
- PYXS N/A
- P/E Ratio
- PMVP N/A
- PYXS N/A
- Revenue Growth
- PMVP N/A
- PYXS N/A
- 52 Week Low
- PMVP $0.81
- PYXS $0.83
- 52 Week High
- PMVP $1.84
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- PMVP 37.45
- PYXS 71.01
- Support Level
- PMVP $1.38
- PYXS $3.17
- Resistance Level
- PMVP $1.47
- PYXS $4.17
- Average True Range (ATR)
- PMVP 0.09
- PYXS 0.31
- MACD
- PMVP -0.03
- PYXS 0.00
- Stochastic Oscillator
- PMVP 0.00
- PYXS 86.08
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.